Seeking Alpha

Rodman & Renshaw weighs in on Curis (CRIS +4.7%) following its unveiling of an agreement...

Rodman & Renshaw weighs in on Curis (CRIS +4.7%) following its unveiling of an agreement with the Leukemia & Lymphoma Society. Analysts with the firm say that funding from the organization will support the development of CUDC-907, as well as add value to early stage pipeline.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)